文献速递冠心病血脂与心血管预防

心肌梗死幸存者延长双联抗血小板治疗决策的个体化:预后模型的开发、验证与潜在影响

Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors.
PubMed 文献 · Eur Heart J · 2017-01-01

基于英国CALIBER电子健康记录(2000-10年),在急性心肌梗死1年后患者中开发并验证心血管事件与出血预后模型,开发队列12694例、验证队列5613例。模型区分度良好(心血管事件c指数0.75,出血0.72),可估算个体延长DAPT的获益与危害,最高危患者每万人年预防249例心血管事件、导致134例大出血。

要点

  • 心血管事件模型c指数0.75(95%CI 0.74-0.77),出血模型c指数0.72(95%CI 0.67-0.77),校准良好。
  • 3年心血管事件风险总体16.5%,最低危5.2%、最高危46.7%;大出血总体1.7%,最低危0.3%、最高危5.4%。
  • 最高危患者每万人年预防249例心血管事件、导致134例大出血;最低危预防28例、导致9例。

核心结论

  • 基于人群电子健康记录的心血管事件与出血预后模型,可能有助于急性心肌梗死1年后延长双联抗血小板治疗决策的个体化。

研究设计与样本

  • 基于英国CALIBER电子健康记录(2000-10年)的人群数据,纳入急性心肌梗死1年后评估的患者,开发队列12694例、验证队列5613例。
  • 开发并验证心血管事件(心血管死亡、心肌梗死或卒中)及三种不同出血终点的预后模型,并应用试验效应估计值评估个体延长DAPT的潜在获益与危害及净临床获益。

主要发现

  • 心血管事件模型c指数0.75(95%CI 0.74-0.77),出血模型c指数0.72(95%CI 0.67-0.77),模型校准良好。
  • 3年心血管事件风险总体16.5%,最低危个体5.2%,最高危个体46.7%。
  • 3年大出血风险总体1.7%,最低危患者0.3%,最高危患者5.4%。
  • 每10000例治疗患者每年,最高危患者估计预防249例(95%CI 228-269)心血管事件、导致134例(95%CI 87-181)大出血事件;最低危患者预防28例(95%CI 19-37)心血管事件、导致9例(95%CI 0-20)大出血事件。
  • 根据获益与危害的权重方式,延长DAPT在63%-99%的患者中存在净临床获益。

关键数值与推荐

  • 心血管事件预后模型c指数0.75(95%CI 0.74-0.77)。
  • 出血预后模型c指数0.72(95%CI 0.67-0.77)。
  • 最高危患者每10000例每年:预防249例(95%CI 228-269)心血管事件,导致134例(95%CI 87-181)大出血事件。
  • 最低危患者每10000例每年:预防28例(95%CI 19-37)心血管事件,导致9例(95%CI 0-20)大出血事件。
  • 延长DAPT的净临床获益见于63%-99%的患者,取决于获益与危害的权重方式。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study is to develop models to aid the decision to prolong dual antiplatelet therapy (DAPT) that requires balancing an individual patient's potential benefits and harms. METHODS AND RESULTS: Using population-based electronic health records (EHRs) (CALIBER, England, 2000-10), of patients evaluated 1 year after acute myocardial infarction (MI), we developed (n = 12 694 patients) and validated (n = 5613) prognostic models for cardiovascular (cardiovascular death, MI or stroke) events and three different bleeding endpoints. We applied trial effect estimates to determine potential benefits and harms of DAPT and the net clinical benefit of individuals. Prognostic models for cardiovascular events (c-index: 0.75 (95% CI: 0.74, 0.77)) and bleeding (c index 0.72 (95% CI: 0.67, 0.77)) were well calibrated: 3-year risk of cardiovascular events was 16.5% overall (5.2% in the lowest- and 46.7% in the highest-risk individuals), while for major bleeding, it was 1.7% (0.3% in the lowest- and 5.4% in the highest-risk patients). For every 10 000 patients treated per year, we estimated 249 (95% CI: 228, 269) cardiovascular events prevented and 134 (95% CI: 87, 181) major bleeding events caused in the highest-risk patients, and 28 (95% CI: 19, 37) cardiovascular events prevented and 9 (95% CI: 0, 20) major bleeding events caused in the lowest-risk patients. There was a net clinical benefit of prolonged DAPT in 63-99% patients depending on how benefits and harms were weighted. CONCLUSION: Prognostic models for cardiovascular events and bleeding using population-based EHRs may help to personalise decisions for prolonged DAPT 1-year following acute MI.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Pasea L, Chung SC, Pujades-Rodriguez M, et al. Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. Eur Heart J. 2017. PMID: 28329300. doi:10.1093/eurheartj/ehw683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。